Explore

Trendline Trendline
CareDx Expands HLA Typing Portfolio with AlloSeq Nano Launch

CareDx Expands HLA Typing Portfolio with AlloSeq Nano Launch

CareDx Expands HLA Typing Portfolio with AlloSeq Nano Launch
Trendline Trendline
CareDx Showcases Precision Medicine Advancements at Heart and Lung Transplantation Meeting

CareDx Showcases Precision Medicine Advancements at Heart and Lung Transplantation Meeting

CareDx Showcases Precision Medicine Advancements at Heart and Lung Transplantation Meeting
Rapid Read Rapid Read
Nature Conference Explores Precision Medicine's Transition from Innovation to Implementation

Nature Conference Explores Precision Medicine's Transition from Innovation to Implementation

The 'Reframing Precision Medicine: Innovation to Implementation' conference, organized by Nature, is set to take place in London. This event aims to bridge the gap between the theoretical advancements in precision medicine and their practical application in healthcare. The conference will focus on how multi-omics, artificial intelligence, and big data are transforming diagnosis and treatment. It will feature global leaders in science, medicine, and policy, discussing the integration of these technologies into clinical practice. The event will also offer training sessions and opportunities for attendees to engage with experts in the field.
Rapid Read Rapid Read
Nanostics Validates AI-Driven Prostate Cancer Prediction Models

Nanostics Validates AI-Driven Prostate Cancer Prediction Models

Nanostics Inc. has announced the publication of a study validating its ClarityDX Prostate models, which use AI to predict aggressive prostate cancer. The study, published in npj Digital Medicine, demonstrates that these models can accurately assess cancer risk, potentially reducing unnecessary biopsies. The models incorporate patient clinical features and laboratory tests, with options to include MRI and digital rectal exam data. The research highlights the models' high accuracy and potential to improve clinical decision-making in prostate cancer screening.
Trendline Trendline
ViewsML Secures $4.9M to Advance AI-Driven Biomarker Staining

ViewsML Secures $4.9M to Advance AI-Driven Biomarker Staining

ViewsML Secures $4.9M to Advance AI-Driven Biomarker Staining
Trendline Trendline
Nanostics Validates ClarityDX Prostate Models for Improved Cancer Prediction

Nanostics Validates ClarityDX Prostate Models for Improved Cancer Prediction

Nanostics Validates ClarityDX Prostate Models for Improved Cancer Prediction
Rapid Read Rapid Read
Nature Conference Explores Precision Medicine's Role in Personalized Care

Nature Conference Explores Precision Medicine's Role in Personalized Care

The Nature Conference titled 'Reframing Precision Medicine: Innovation to Implementation' is set to explore the advancements in personalized medicine. The event will focus on how multi-omics, artificial intelligence, and big data are reshaping diagnosis, treatment, and recovery across the human life course. Precision medicine has evolved beyond its initial promise, with genomics, transcriptomics, proteomics, metabolomics, and spatial omics now mature enough to inform clinical decisions. The conference aims to address the challenges health systems face in implementing these tools at scale, emphasizing ethical, inclusive, and clinically meaningful approaches. Global leaders in precision medicine research and clinical translation will gather to redefine patient care through data, technology, and biological insights.
Rapid Read Rapid Read
Seegene Unveils STAgora at ESCMID Global 2026, Showcasing Real-Time Data Integration in PCR Workflows

Seegene Unveils STAgora at ESCMID Global 2026, Showcasing Real-Time Data Integration in PCR Workflows

Seegene, a global leader in molecular diagnostics, introduced its new real-time data analytics platform, STAgora, at the ESCMID Global 2026 conference in Munich, Germany. The platform is designed to enhance the understanding of infectious disease trends by integrating real-time data analytics with automated PCR testing infrastructure. Alongside STAgora, Seegene presented an enhanced model of its automated PCR workflow system, CURECA. The event attracted significant interest from healthcare professionals, laboratory specialists, and industry stakeholders, who engaged with the interactive demonstrations of STAgora's capabilities. The platform allows for the visualization of aggregated testing data, offering insights into regional infection trends and pathogen-specific positivity rates. Seegene's approach aims to connect PCR testing data globally, providing a comprehensive view of infection patterns.
Trendline Trendline
Castle Biosciences Unveils Data on DecisionDx-Melanoma for Early-Stage Melanoma Risk Assessment

Castle Biosciences Unveils Data on DecisionDx-Melanoma for Early-Stage Melanoma Risk Assessment

Castle Biosciences Unveils Data on DecisionDx-Melanoma for Early-Stage Melanoma Risk Assessment
Trendline Trendline
SAGA Diagnostics to Present New Data on Cancer Detection at AACR 2026

SAGA Diagnostics to Present New Data on Cancer Detection at AACR 2026

SAGA Diagnostics to Present New Data on Cancer Detection at AACR 2026
Trendline Trendline
Caris Life Sciences to Announce Q1 2026 Financial Results, Highlighting Precision Medicine Advances

Caris Life Sciences to Announce Q1 2026 Financial Results, Highlighting Precision Medicine Advances

Caris Life Sciences to Announce Q1 2026 Financial Results, Highlighting Precision Medicine Advances
Rapid Read Rapid Read
Advancements in Molecular Residual Disease Testing Offer New Insights for Breast Cancer Treatment

Advancements in Molecular Residual Disease Testing Offer New Insights for Breast Cancer Treatment

Recent developments in the field of precision oncology have highlighted the potential of Molecular Residual Disease (MRD) testing in managing triple-negative breast cancer (TNBC), one of the most aggressive breast cancer subtypes. According to findings presented at the American Association for Cancer Research Annual Meeting, MRD testing, particularly through the use of circulating tumor DNA (ctDNA) status, provides significant insights into treatment response and recurrence risk. The study, part of the NSABP-B-59/GBG-96-GeparDouze trial, revealed that patients who were ctDNA-negative after neoadjuvant therapy were more likely to achieve a pathologic complete response at surgery. Conversely, those who remained ctDNA-positive faced a higher risk of distant recurrence. This testing method offers a new layer of biological insight beyond traditional imaging and pathology, which often cannot detect microscopic disease post-treatment.